Combination of an inhibitor of HMG-CoA reductase and a farnesyl-pyrophosphatase synthase inhibitor for the treatment of diseases related to the persistence and / or accumulation of prenylated proteins

摘要

Composition comprising a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and a farnesyl pyrophosphate synthase inhibitor, or a physiologically acceptable salt thereof, for use in the treatment of pathological conditions that involve signs of aging, since whether natural, premature or accelerated selected from the deterioration of the vascular endothelium, skin aging and bone lysis, related to the accumulation and / or persistence in progerin and / or farnesylated A prelamine A cells.